Reconciling the risk of QT interval prolongation in antidepressants.
about
Pediatric drug safety signal detection: a new drug-event reference set for performance testing of data-mining methods and systems.How much to worry about the FDA warning in the use of citalopram?Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram.Safety of selective serotonin reuptake inhibitor treatment in recovering stroke patients.
P2860
Reconciling the risk of QT interval prolongation in antidepressants.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Reconciling the risk of QT interval prolongation in antidepressants.
@en
Reconciling the risk of QT interval prolongation in antidepressants.
@nl
type
label
Reconciling the risk of QT interval prolongation in antidepressants.
@en
Reconciling the risk of QT interval prolongation in antidepressants.
@nl
prefLabel
Reconciling the risk of QT interval prolongation in antidepressants.
@en
Reconciling the risk of QT interval prolongation in antidepressants.
@nl
P2093
P356
P1476
Reconciling the risk of QT interval prolongation in antidepressants.
@en
P2093
P2860
P304
329-30; author reply 331-2
P356
10.1002/PDS.3216
P577
2012-03-01T00:00:00Z